Partner 12: Yecuris Corporation (Yecuris)
Yecuris Corporation is one of the worlds leading developers of humanised xenograft animal technologies and supplies tools to researchers around the globe. Markus Grompe serves as the organisations Chief Scientific Officer and is a world expert in human genetics and stem cell technologies. John Bial is the Chief Executive Officer and is responsible for all administrative tasks associated with the project. Elizabeth Wilson is the Senior Scientist in the lab and oversees daily scientific operations. The facilities are built to house up to 15,000 small animal models and are fully equipped to perform transplantation and analysis services.
Partner 12 team leaders:
John R. Bial
Elizabeth M. Wilson
Yecuris Corporation will interface with the HUMAN consortium to provide humanised xenograft models of the liver utilising ethically procured primary and iPSC-derived materials to investigators in the project. Further, Yecuris Corporation will utilise its expertise in xenograft technologies to pioneer new methods in engraftment suitable to iPSC-derived cell populations.
Yecuris Corporation has been in operation since 2007 and provides humanised xenograft mice and services to the worlds leading pharmaceutical and research institutions. Further, they provide custom engraftment of client derived materials and have extensive experience in the engraftment of iPSC-derived materials. More recently, the FRG™ model has been shown to be useful in a variety of areas including hepatocyte expansion, drug metabolism, infectious disease, toxicology, and safety applications. To date, the lack of a supply of robust primary hepatic materials and models has been an impediment to basic scientific research, timely delivery of drug candidates and cures, and the development of novel treatments for chronic and acute liver disease. The introduction of the Yecuris™ FRG mouse represents a significant advancement in the ability to provide researchers and clinicians with a dependable supply of these precious materials. Our team of dedicated research and business professionals is committed to supporting HUMAN and providing validated mouse models developed by HUMAN to the market and developing next generation solutions that allow for improved utility and physiological relevance.
1. Vaughan A., et al. (2012) Complete Plasmodium falciparum liver stage development in liver-chimeric mice. Journal of Clinical Investigation. 122(10):3618-28.
2. Bissig D., et al. (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. Journal of Clinical Investigation. 120(3):924-930.
3. Azuma H., et al. (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nature Biotechnology. 25(8):903-910.